CTO / co-founder
Perfuze
Perfuze is developing a superbore aspiration catheter designed for efficient access to occluded brain arteries during acute ischemic stroke treatment, enhancing the potential for complete clot removal. This technology addresses the significant challenge of achieving positive clinical outcomes, as less than 50% of stroke patients currently benefit from existing therapies.
- Biotechnology
- Medical Devices
Updated 23 months ago
Funding
Raised to date
$23.9MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Acute ischemic stroke treatment is often hampered by incomplete clot removal, leading to poor patient outcomes, with less than 50% of patients achieving positive results with existing therapies. Current methods may not efficiently access and remove clots from occluded brain arteries.
Solution
Perfuze is developing a superbore aspiration catheter designed to enhance the efficiency of accessing and removing blood clots in acute ischemic stroke patients. The device aims to simplify the process of reaching and extracting clots from occluded brain arteries, increasing the likelihood of complete clot removal during thrombectomy procedures. By improving the speed and effectiveness of clot retrieval, Perfuze seeks to improve overall patient outcomes and reduce disability following a stroke. The catheter is designed for ease of use and repeatability in clinical settings.
Target Audience
The primary target audience includes neurointerventional radiologists and vascular surgeons who perform thrombectomy procedures for acute ischemic stroke.
Features
- Superbore aspiration catheter design for improved access to occluded vessels
- Enhanced clot ingestion capabilities for more complete removal
- Designed to simplify and streamline clot removal procedures